KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Total Current Liabilities (2016 - 2026)

Bristol Myers Squibb has reported Total Current Liabilities over the past 18 years, most recently at $19.2 billion for Q1 2026.

  • Quarterly Total Current Liabilities fell 20.41% to $19.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $19.2 billion through Mar 2026, down 20.41% year-over-year, with the annual reading at $23.4 billion for FY2025, 1.5% down from the prior year.
  • Total Current Liabilities was $19.2 billion for Q1 2026 at Bristol Myers Squibb, down from $23.4 billion in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $28.1 billion in Q3 2025 and troughed at $18.9 billion in Q3 2022.
  • The 5-year median for Total Current Liabilities is $22.8 billion (2022), against an average of $22.8 billion.
  • Year-over-year, Total Current Liabilities soared 35.3% in 2024 and then fell 20.41% in 2026.
  • A 5-year view of Total Current Liabilities shows it stood at $21.9 billion in 2022, then rose by 1.7% to $22.3 billion in 2023, then grew by 6.79% to $23.8 billion in 2024, then dropped by 1.5% to $23.4 billion in 2025, then dropped by 18.19% to $19.2 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Total Current Liabilities are $19.2 billion (Q1 2026), $23.4 billion (Q4 2025), and $28.1 billion (Q3 2025).